论文部分内容阅读
目的 探讨前列腺特异抗原(tPSA)、游离PSA(fPSA)以及fPSA/tPSA在前列腺癌(PCa)诊断和疗效监测中的临床价值。方法 采用全自动化学发光免疫分析仪测定36例正常人、42例前列腺增生(BPH)和44例前列腺癌患者tPSA、fPSA,并计算fPSA/tPSA比值。同时,对29例前列腺癌患者术后tPSA、fPSA进行动态监测。结果 fPSA/tPSA对PCa诊断的特异性为88.1％,诊断指数为0.79,显著高于单独tPSA(P<0.05)。结论 fPSA/tPSA的引入提高了对PCa诊断的特异性,动态监测是提示肿瘤是否转移与复发最理想的指标。
Objective To investigate the clinical value of prostate specific antigen (tPSA), free PSA (fPSA) and fPSA / tPSA in the diagnosis and curative effect of prostate cancer (PCa). Methods The levels of tPSA and fPSA were measured in 36 normal subjects, 42 benign prostatic hyperplasia (BPH) and 44 prostatic cancer patients by using chemiluminescence immunoassay. The fPSA / tPSA ratio was calculated. At the same time, 29 cases of prostate cancer patients after tPSA, fPSA dynamic monitoring. Results The specificity of fPSA / tPSA in diagnosing PCa was 88.1% and the diagnostic index was 0.79, which was significantly higher than that of tPSA alone (P <0.05). Conclusion The introduction of fPSA / tPSA improves the specificity of PCa diagnosis. Dynamic monitoring is the best indicator of tumor metastasis and recurrence.